American Century Companies Inc. Has $300.78 Million Stake in Cencora, Inc. $COR

American Century Companies Inc. lessened its stake in Cencora, Inc. (NYSE:COR) by 6.3% in the third quarter, Holdings Channel reports. The firm owned 962,413 shares of the company’s stock after selling 64,790 shares during the quarter. American Century Companies Inc.’s holdings in Cencora were worth $300,784,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Cornerstone Wealth Group LLC increased its stake in Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after acquiring an additional 30 shares during the last quarter. Security Financial Services INC. lifted its stake in shares of Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after acquiring an additional 33 shares during the period. Hemington Wealth Management boosted its stake in shares of Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after purchasing an additional 35 shares during the last quarter. Quadcap Wealth Management LLC lifted its stake in shares of Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after purchasing an additional 36 shares during the period. Finally, Howard Capital Management Inc. lifted its stake in shares of Cencora by 2.5% in the 3rd quarter. Howard Capital Management Inc. now owns 1,499 shares of the company’s stock valued at $468,000 after purchasing an additional 37 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR stock opened at $371.86 on Friday. The company has a market capitalization of $72.34 billion, a P/E ratio of 44.69, a PEG ratio of 1.71 and a beta of 0.68. Cencora, Inc. has a fifty-two week low of $248.59 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The stock has a 50 day moving average price of $351.72 and a two-hundred day moving average price of $333.58.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same period in the previous year, the firm earned $3.73 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio is 28.85%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on COR shares. Wells Fargo & Company increased their price target on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Barclays boosted their target price on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Finally, Evercore decreased their price target on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $399.00.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 15,220 shares of company stock worth $5,282,867. Company insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.